

Engineered cardiac model systems for dilated cardiomyopathy

Citation for published version (APA):

Spreeuwel, van, A. C. C., Bax, N. A. M., Schaft, van der, D. W. J., & Bouten, C. V. C. (2011). *Engineered cardiac model systems for dilated cardiomyopathy*. Poster session presented at Mate Poster Award 2011 : 16th Annual Poster Contest.

Document status and date:

Published: 01/01/2011

Document Version:

Accepted manuscript including changes made at the peer-review stage

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy


If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.

Engineered cardiac model systems for dilated cardiomyopathy

A.C.C van Spreeuwel, N.A.M. Bax, D.W.J van der Schaft, C.V.C Bouten



Introduction

Dilated cardiomyopathy (DCM) is characterized by diminished contractile function and progressive enlargement of the heart. It is the leading cause of heart failure and DCM patients suffer from arrhythmia and risk a sudden death^[1]. The goal of this project is to develop an engineered cardiac model system of healthy and dilated cardiac tissue to perform studies on the effect of DCM on mechanical properties resulting from changes in cell-cell and cell-matrix interactions.





Fig 1. Project overview: To create an engineered cardiac model system, we will characterize the native environment of cardiomyocytes in healthy and diseased tissue. Furthermore HL-1 murine cardiomyocytes will be used as healthy cells, and they can be transfected or treated with drugs to induce 'disease'.

Native Tissue properties

The composition, architecture and mechanical properties of healthy and diseased cardiac tissue from mouse models, as well as from human cardiac biopsies, will be determined to mimic the native environment of cardiac cells in engineered cardiac models system.




Figure 2: Results of initial indentation tests on porcine myocardium.

Tissue stiffness will be determined using indentation tests (fig. 2), which can be related to the matrix composition, as determined by histology (fig. 3). Furthermore, tissue composition in both healthy and diseased myocardium will be studied by performing immunohistochemistry.




Figure 3: Masson's Trichrome staining on healthy (A) and diseased (B) mouse myocardium with cells in red and collagen in blue. Diseased tissue had more collagen and a more chaotic structure compared to healthy tissue.

Healthy and diseased cells

The HL-1 murine cardiomyocyte cell line, will be used to develop our engineered cardiac model system. Since this cell line has been studied in 2D only^[2,3], we will start by investigating the application for making 3D constructs (fig.4).




Figure 4: HL-1 cells in 2D (A) and in a 3D hydrogel (B) stained for actin in red and nuclei in blue. HL-1 cells in 2D have a more spread morphology and more stress fibers, compared to 3D, where the cells have a more round morphology.

Future Research

Different mouse models for DCM will be characterized by immunohistochemistry and indentation tests to provide input for the engineered cardiac model system. The HL-1 cardiomyocytes will be used to make 3D cardiac tissue models to perform studies on the effect of DCM on cell-cell and cell-matrix interactions.